Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 3/20 | 0.70 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29407529 | 1.00 | ESR2 (0.70) | ESR2NR1H2MAPK1ABHD6HDAC1 | |
| SCHEMBL29407557 | 0.95 | NR1H2 (0.69) | ESR2NR1H2MAPK1ABHD6HDAC1 | |
| SCHEMBL1285596 | 0.95 | NR1H2 (0.69) | ESR2NR1H2MAPK1ABHD6HDAC1 | |
| SCHEMBL1787313 | 0.92 | ESR2 (0.59) | ESR2NR1H2GPR119HDAC6NPC1 | |
| SCHEMBL1365302 | 0.90 | ESR2 (0.67) | ESR2NR1H2MAPK1ABHD6HDAC1 | |
| SCHEMBL14768550 | 0.90 | ESR2 (0.70) | ESR2NR1H2MAPK1ABHD6HDAC1 | |
| SCHEMBL29974005 | 0.89 | ESR2 (0.54) | ESR2NR1H2MAPK1HDAC1GPR119 | |
| SCHEMBL1650190 | 0.89 | ESR2 (0.54) | ESR2NR1H2MAPK1HDAC1GPR119 | |
| SCHEMBL166101 | 0.89 | ESR2 (0.69) | ESR2NR1H2MAPK1ABHD6HDAC1 | |
| SCHEMBL1773518 | 0.89 | ESR2 (0.69) | ESR2NR1H2MAPK1ABHD6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12544448-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4651955-A1 | INHIBITOR COMPOUNDS | Neophore Limited (GB) | 2025-11-26 | — | — | EP | disclosed |
| US-20250325687-A1 | CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST | MABSOFT THERAPEUTICS SHANGHAI CO LTD (CN) | 2025-10-23 | — | — | US | disclosed |
| EP-3463362-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME LLC (US) | 2025-09-03 | — | — | EP | disclosed |
| CN-115279766-B | Combination therapy comprising A2A/A2B and a PD-1/PD-L1 inhibitor | 因赛特公司 | 2025-05-02 | — | — | CN | disclosed |
| US-20250108117-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-04-03 | — | — | US | disclosed |
| US-20250059293-A1 | CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY | INCYTE CORPORATION | 2025-02-20 | — | — | US | disclosed |
| EP-4508061-A1 | CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST | Mabsoft Therapeutics (Shanghai) Co., Ltd. (CN) | 2025-02-19 | — | — | EP | disclosed |
| US-20250041310-A1 | Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors | INCYTE CORPORATION | 2025-02-06 | — | — | US | disclosed |
| CN-119365479-A | Conjugates comprising Toll-like receptor agonists | 慕宝盛科生物医药(上海)有限公司 | 2025-01-24 | — | — | CN | disclosed |
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| WO-2009001128-A1 | 1,2-CYCL0HEXANE DICARBOXAMIDES AS CATHEPSIN INHIBITORS | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
| EP-1644367-A4 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2008-12-31 | — | — | EP | disclosed |
| US-7462629-B2 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2008-12-09 | — | — | US | disclosed |
| US-20070190523-A1 | Method and compositions for identifying anti-hiv therapeutic compounds | GILEAD SCIENCES, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| EP-1644367-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2006-04-12 | — | — | EP | disclosed |
| US-20050009786-A1 | Immunosuppressant compounds and compositions | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2005-01-13 | — | — | US | disclosed |
| WO-2004113330-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059293-A1 | CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY | ADORA2A, ADORA2B, NT5E | ESR2 769/4885NR1H2 4376/4885MAPK1 4392/4885 |
| US-20250108117-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | MTOR, RICTOR, RPTOR | ESR2 2077/4885NR1H2 3048/4885MAPK1 604/4885 |
| US-20250041310-A1 | Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors | ADORA2A, ADORA2B, ADORA1 | ESR2 850/4885NR1H2 3389/4885MAPK1 2603/4885 |
| US-20050009786-A1 | Immunosuppressant compounds and compositions | ICOS, EDNRA, NFATC1 | ESR2 659/4885NR1H2 1070/4885MAPK1 1043/4885 |
| US-20250325687-A1 | CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST | TLR3, TLR7, TLR8 | ESR2 418/4885NR1H2 214/4885MAPK1 2321/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | ESR2 4551/4885NR1H2 4224/4885MAPK1 2930/4885 |
| US-12544448-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | RICTOR, MTOR, MLST8 | ESR2 3687/4885NR1H2 2545/4885MAPK1 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.